# A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Source: https://onco.cc/trials/nct05736731/  
OnCo record `nct05736731` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of A2B530 in pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, run by A2 Biotherapeutics Inc., active and no longer recruiting.

## Summary

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression is a phase 1/2 interventional study registered as NCT05736731 by A2 Biotherapeutics Inc., with 160 participants enrolled, started 2023-04-28 and due to reach its primary completion in 2026-12. Interventions recorded: A2B530.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05736731
- Phase: 1/2
- Setting: A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530, an Autologous Logic-gated Tmod™ Chimeric Antigen Receptor T Cell (CAR T), in Heterozygous HLA-A*02 Adult Subjects With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
- Sponsor: A2 Biotherapeutics Inc.
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT05736731: https://clinicaltrials.gov/study/NCT05736731

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Tempus AI](https://onco.cc/companies/tempus/)

---
JSON: https://onco.cc/api/v1/entities/nct05736731.json